Allogene Therapeutics is developing an off-the-shelf CAR-T therapy that is nearing early but pivotal trial evaluation[1]. Preliminary data from the study could confirm the firm's faith in mainstream CAR-T therapy[1]. In 2026, he expects key milestones for the allogeneic CAR-T platform in oncology and autoimmune diseases[1]. For ALLO-316 in renal cell carcinoma, a 31% confirmed objective response is reported in patients with high CD70 expression in the phase 1 TRAVERSE trial[1]. For ALLO-329, a dual CD19/CD70 AlloCAR T product for autoimmune diseases, it plans initial proof-of-concept data by mid-2026, with Dagger technology to reduce lymphodepletion[1]. The company has financial resources until the second half of 2027[1].